TG Therapeutics Inc (TGTX)
Interest coverage
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 25,677 | -192,839 | -344,770 | -273,594 | -167,583 |
| Interest expense | US$ in thousands | 12,615 | 10,191 | 5,638 | 6,329 | 5,287 |
| Interest coverage | 2.04 | -18.92 | -61.15 | -43.23 | -31.70 |
December 31, 2023 calculation
Interest coverage = EBIT ÷ Interest expense
= $25,677K ÷ $12,615K
= 2.04
TG Therapeutics Inc's interest coverage ratio has shown significant volatility over the past five years. The ratio improved from -61.15 in 2021 to 2.04 in 2023, indicating the company's ability to cover its interest expenses has strengthened. However, the negative ratios in 2020 and 2019 suggest that the company was unable to cover its interest obligations with its operating income during those years. It is essential for the company to maintain a healthy interest coverage ratio to demonstrate its ability to meet its debt obligations and avoid financial distress. Overall, the fluctuating trend in the interest coverage ratio requires close monitoring to assess the company's financial stability and debt repayment capacity.
Peer comparison
Dec 31, 2023